New drug combo aims to slow cervical cancer growth

NCT ID NCT06266338

Recruiting now Disease control Sponsor: University of Texas Southwestern Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing whether two drugs, pembrolizumab (Keytruda) and lenvatinib (Lenvima), can slow tumor growth in people with cervical cancer that has spread or come back. About 30 participants will receive the combination. The main goal is to see how many people's tumors shrink or stop growing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pembrolizumab (Keytruda) and lenvatinib (Lenvima)
What this could lead to: If successful, this drug combination could offer a new treatment option to slow tumor growth in people with advanced cervical cancer that has returned or spread.
What could go wrong: This is a small, early-phase (phase 2) study with only 30 participants, so results may not apply to everyone. The combination may cause side effects and might not work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cervical cancer cervical carcinoma Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CERVICAL CANCER CERVIX CANCER

Contacts and locations

Locations

UT Southwestern Medical Center
RECRUITING

Dallas, Texas, 75390, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.